Paloma Partners Management Co purchased a new position in Endo International plc – (NASDAQ:ENDP) (TSE:ENL) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 15,814 shares of the company’s stock, valued at approximately $122,000.
A number of other large investors have also modified their holdings of the stock. Quantitative Investment Management LLC acquired a new position in Endo International in the 4th quarter worth approximately $1,569,000. Amundi Pioneer Asset Management Inc. increased its holdings in Endo International by 235.6% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 96,033 shares of the company’s stock worth $745,000 after buying an additional 67,415 shares during the period. Hudson Bay Capital Management LP acquired a new position in Endo International in the 4th quarter worth approximately $388,000. Systematic Financial Management LP increased its holdings in Endo International by 22.5% in the 4th quarter. Systematic Financial Management LP now owns 190,550 shares of the company’s stock worth $1,477,000 after buying an additional 35,045 shares during the period. Finally, UBS Asset Management Americas Inc. increased its holdings in Endo International by 4.4% in the 4th quarter. UBS Asset Management Americas Inc. now owns 221,992 shares of the company’s stock worth $1,720,000 after buying an additional 9,438 shares during the period. Institutional investors own 94.72% of the company’s stock.
Several equities analysts recently weighed in on ENDP shares. Mizuho reiterated a “buy” rating and issued a $12.00 price target (down previously from $14.00) on shares of Endo International in a report on Wednesday, January 3rd. Leerink Swann started coverage on shares of Endo International in a report on Tuesday, January 2nd. They issued an “outperform” rating and a $12.00 price target on the stock. Vetr upgraded shares of Endo International from a “buy” rating to a “strong-buy” rating and set a $8.92 price target on the stock in a report on Tuesday, December 26th. Zacks Investment Research lowered Endo International from a “hold” rating to a “sell” rating in a research report on Monday, January 15th. Finally, BidaskClub lowered Endo International from a “sell” rating to a “strong sell” rating in a research report on Wednesday, January 31st. Three equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $9.68.
Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its earnings results on Tuesday, February 27th. The company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.15. Endo International had a positive return on equity of 81.03% and a negative net margin of 58.68%. The firm had revenue of $768.64 million for the quarter, compared to analyst estimates of $762.29 million. During the same quarter last year, the firm posted $1.77 EPS. The business’s revenue was down 38.1% on a year-over-year basis. sell-side analysts expect that Endo International plc – will post 2.33 EPS for the current fiscal year.
About Endo International
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.